This Month, I’d like to introduce you to the company, Reglagene, www.reglagene.com, a therapeutics company located in Tucson, AZ transforming tubulin targeting therapy for CNS diseases. Their pipeline also includes disease indications driven by brain inflammation. My personal ask is if you are an investor in healthcare with a desire to support and advance patient access to treatments because patients deserve better therapies that improve Quality of Life (QOL) as well as extend life, please contact directly Co-founder & CEO, Richard Austin at info@reglagene.com, #RichardAustin, #Reglagene. Reglagene is also seeking a Chief Medical Officer to move their GBM molecule into human clinical trials. Please send resume to Richard at the above email address if you are interested in learning more.
Reglagene’s lead program is a novel, orally administered, first-in-class well tolerated, blood brain barrier (BBB) penetrant therapy for the treatment of brain cancers including GBM and metastasized disease to the brain. To learn more, go to www.EndBrainCancer.org and type in the search bar “Reglagene”. There also an informative Reglagene video available on the web.
THANK YOU for your support to increase Patient ACCESS!!!
Dellann Elliott Mydland
President & Board Chair
The EndBrainCancer Initiative | Chris Elliott Fund
Dellann@EndBrainCancer.org
